BioMarin lands three-year deal for German coverage of gene therapy at $900K per patient
BioMarin announced a new three-year deal on Tuesday with the German National Association of Statutory Health Insurance Funds (GKV-SV), which covers about 90% of the German population, for reimbursement of its gene therapy Roctavian (valoctocogene roxaparvovec-rvox) for patients with severe hemophilia A.
The California-based company said its one-time, single-dose therapy delivered via intravenous infusion over three to four hours will have a gross price of €28,933.53 (about $31,780) per vial in Germany. That translates to about $900,000 in net revenue per patient for BioMarin at the current exchange rate, the company said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.